Figure 1
BI 836826 efficacy in SP and non-SP B leukemic cells from relapsed patients. (a) CD37 expression in SP and non-SP cells: cells were labeled with Hoechst 33342 in the presence or not of Verapamil5, 10 with control Isotype or FITC BI 836826 antibody (n=7). (b) Antibody-induced B-cell depletion: fresh PBMC were incubated in the presence of IgG control, RTX, BI 836826 or BI 836847 (isotype control) (10 μg/ml) for 7 days. Antibody-mediated B-cell depletion was determined by enumerating trypan blue-negative combined to CD5/CD19-positive B lymphocytes, determination by flow cytometry7 (n=18). (c) Antibody-induced B-cell depletion in SP and non-SP populations: fresh PBMC were incubated in the presence of 10 μg/ml BI 836826 or BI 836847 (isotype control) (10 μg/ml) for 7 days and then processed for SP and non-SP analysis and quantification (n=9). (d) SP and non-SP quantification in BI 836826-treated patients (n=3). Flow cytometric experiments were done on a FACS BDLSR2 or FORTESSA X20 (Becton Dickinson) and analysed by DIVA software. Statistical analysis: paired Student t-test. **P<0.001; ***P<0.005; ****P<0.0001.
